RGCC stands for Research Genetics Cancer Center. We prefer RGCC.

If you have any medical concerns, you should speak to a qualified medical professional urgently. For personalized information about cancer diagnosis, tests, and treatments, we recommend scheduling a consultation with an RGCC network clinician. To find an RGCC network clinician near you, please fill out this form and a member of our team will get in touch with you shortly. 

The Onconomics, Onconomics Plus, and Oncononomics Extracts+ tests look for the expression of genes that are linked with the effect of specific drugs on the cancer cells in a single patient. 

Once you have ordered an RGCC test, an RGCC clinician within our network will take the required test sample. They will be provided with all shipping instructions to ensure the sample arrives at our labs in perfect condition. The sample is processed at one of our world-leading laboratories. Once the test is completed, we provide your clinician with a detailed breakdown of the findings. Based on these findings, your clinician will develop a personalized treatment plan for you. You can learn more about the RGCC test process by visiting the RGCC test pages.

The Onconomics Plus test provides information on how effective specific anti-cancer drugs, targeted therapies, and natural treatments are on the cancer cells in an individual patient. The ChemoSNiP test can be used to predict whether a patient will respond to drugs and metabolize them properly. 

Explore the comprehensive data we have published and presented at medical conferences by visiting this link. 

None of the RGCC tests require both blood and tissue samples. However, tissue samples can be useful in specific cases. For example, in brain cancer cases, in which CTC cannot be detected. In those cases, an Onconomics test, for example, can be performed on isolated cancer cells of the tissue sample.

However, it's good to note that the CTCs from blood samples provide a broader understanding of the disease, while tissue samples offer localized information specific to the tumor site. Therefore, providing a tissue sample vs a blood sample depends on whether you would like to focus on a specific tumor site. Since the biological sources differ, the resulting data may also vary.

Our tests encompass all solid and blood tumor malignancies (including lung, breast, prostate, colorectum, prostate, stomach, liver, cervix uteri, oesophagus, thyroid, bladder, etc). This excludes primary tumors of the central nervous system for which cerebrospinal fluid can be used.

We calculate the number of circulating tumor cells from the total amount of blood cells, expressed as the volume of circulating tumor cells per milliliter of blood. This cannot be calculated from a tissue sample. To conduct a circulating tumor cell test, a blood sample must be provided.

Patients must wait at least 14 days after completing chemotherapy treatment before taking an RGCC test.

The Onconomics family of tests can measure the efficiency of different agents against a patient’s cancer.

For identifying active substances and drugs effective against a tumor. You might find the Onconomics, Onconomics Plus, Onconomics Extracts and Oncononomics Extracts+ tests useful.